TP53 and colorectal carcinoma: We therefore sought to evaluate the combined antitumor efficacy of MDM2 inhibition (KRT-232) and MEK inhibition (selumetinib) in both CRC and PTC with MAPK alterations and with TP53 WT in both cell lines and PDXs.